Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Tiffany, Farchione"'
Autor:
Mathangi Gopalakrishnan, Tiffany Farchione, Mitchell Mathis, Hao Zhu, Mehul Mehta, Ramana Uppoor, Islam Younis
Publikováno v:
Psychiatric Research and Clinical Practice, Vol 3, Iss 1, Pp 38-45 (2021)
Objective To evaluate the performance of the individual Positive and Negative Symptom Scale (PANSS) items, and to assess the feasibility of using a shortened version of the PANSS as an alternative regulatory endpoint for evaluating the efficacy of dr
Externí odkaz:
https://doaj.org/article/53a5f11ac7b84af498eaab89bca9de76
Publikováno v:
The Journal of Clinical Pharmacology. 61
Pediatric labeling information for novel atypical antipsychotics can be significantly delayed as the result of time lag between initial drug approval in adults and the completion of pediatric clinical trials. This delay can lead health care providers
Publikováno v:
New England Journal of Medicine. 381:1-4
Esketamine for Treatment-Resistant Depression The FDA has approved esketamine, the first antidepressant in a new class, for treatment-resistant depression. The agency weighed the drug’s rapid onset...
Autor:
Tiffany Farchione, Valentina Mantua
Publikováno v:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 48
Autor:
Evdokia Anagnostou, Isctm, Tiffany Farchione, Declan G. Murphy, Celso Arango, Valentina Mantua, James T. McCracken, James C. McPartland, Gahan Pandina, Geraldine Dawson, Jeremy Veenstra-VanderWeele
Publikováno v:
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 48
In 2017, facing lack of progress and failures encountered in targeted drug development for Autism Spectrum Disorder (ASD) and related neurodevelopmental disorders, the ISCTM with the ECNP created the ASD Working Group charged to identify barriers to
Autor:
Mehul Mehta, Tiffany Farchione, Islam R. Younis, Mitchell V. Mathis, Hao Zhu, Mathangi Gopalakrishnan, Ramana S. Uppoor
Publikováno v:
JAMA Psychiatry
Importance Facilitating the development of safe and effective medications for schizophrenia is a public health imperative. Objectives To evaluate the association of shortening randomized clinical trial (RCT) duration with the modification of the Posi
Autor:
Mehul Mehta, Yaning Wang, Mathangi Gopalakrishnan, Ramana S. Uppoor, Mitchell V. Mathis, Hao Zhu, Islam R. Younis, Tiffany Farchione, Shamir N. Kalaria
Publikováno v:
Journal of clinical pharmacologyReferences. 60(7)
Despite agreement that early-onset schizophrenia is continuous with the adult-onset form, quantitative relationships between antipsychotic exposure and clinical response are relatively unexplored in adolescents, compared to adults. Clinical efficacy
Autor:
Yaning Wang, Liang Li, Ramana S. Uppoor, Mehul Mehta, Mitchell V. Mathis, Hao Zhu, Tiffany Farchione
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 44:245-262
The aim of the study was to evaluate the exposure-response (E-R) relationships of blood pressure (BP) and heart rate (HR) changes in healthy adults taking methylphenidate (MPH). Intensive time profiles of BP and HR from healthy adults in placebo and
Autor:
Mitchell V. Mathis, Islam R. Younis, Mathangi Gopalakrishnan, Ramana S. Uppoor, Mehul Mehta, Hao Zhu, Tiffany Farchione
Publikováno v:
The Journal of clinical psychiatry. 81(2)
Objective Concerns of increasing placebo response and declining treatment effect in acute schizophrenia trials have been reported for new drug applications (NDAs) submitted to the US Food and Drug Administration (FDA) during an 18-year period from 19
Autor:
Ramana S. Uppoor, Tiffany Farchione, Islam Younis, Mitchell V. Mathis, Mathangi Gopalakrishnan, Mehul Mehta, Hao Zhu, Shamir N. Kalaria
Publikováno v:
Clinical pharmacology and therapeutics. 106(5)
Early-onset schizophrenia, or "adolescent schizophrenia," has a global incidence ranging up to 4% of all schizophrenia cases. Clinical data from antipsychotic programs were collected from new drug applications submitted to the US Food and Drug admini